Accredo Therapeutics®, a specialty pharmacy, is the exclusive provider of Flolan® (epoprostenol sodium) for Injection. This unique partnership allows all FLOLAN patients and treating physicians to benefit from the comprehensive services that Accredo has to offer.

Specialty pharmacy of choice1

  • FLOLAN is distributed to patients exclusively through the Accredo Therapeutics specialty pharmacy
  • With over 20 years of experience as a specialty pharmacy, Accredo Therapeutics is the only national network of pharmacies dedicated to the treatment of PAH

Accredo patient support programs1

  • Clinicians focused on and specifically trained in PAH therapies
  • Extensive network of local pharmacies to serve patients with PAH
  • National customer support center providing 24-hour access to clinical support for patients, family members, and caregivers

ACCREDO Therapeutics

Reference: 1. From: Accredo Therapeutics, Inc. website. Available at: http://www.accredotx.com/home.html. Accessed on July 22, 2008.

Accredo Therapeutics is a division of Accredo Health Group, Inc., a wholly owned subsidiary of Medco Health Solutions, Inc. Accredo Therapeutics is a registered trademark of Accredo Health, Inc.

INDICATION: FLOLAN is indicated for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.


IMPORTANT SAFETY INFORMATION:
Chronic use of FLOLAN is contraindicated in patients with congestive heart failure due to severe left ventricular systolic dysfunction.

FLOLAN should not be used chronically in patients who develop pulmonary edema during dose initiation.

FLOLAN must be reconstituted only as directed using STERILE DILUENT for FLOLAN. FLOLAN must not be reconstituted or mixed with any other parenteral medications or solutions prior to or during administration.

Abrupt withdrawal or reductions in delivery of FLOLAN, as well as overdoses, may result in hemodynamic instability, including rebound pulmonary hypertension or fatal hypotension.

FLOLAN should be used only by clinicians experienced in the diagnosis and treatment of pulmonary hypertension.

FLOLAN is a potent inhibitor of platelet aggregation. Therefore, an increased risk for hemorrhagic complications should be considered, particularly for patients with other risk factors for bleeding.

During chronic use, FLOLAN is delivered continuously on an ambulatory basis through a permanent indwelling central venous catheter. Unless contraindicated, anticoagulant therapy should be administered to PPH and PH/SSD patients receiving FLOLAN to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. In order to reduce the risk of infection, aseptic technique must be used in the reconstitution and administration of FLOLAN as well as in routine catheter care. Dosage of FLOLAN during chronic use should be adjusted at the first sign of recurrence or worsening of symptoms.

Chronic adverse events reported during clinical trials include headache, jaw pain, flushing, diarrhea, nausea and vomiting, flu-like symptoms, and anxiety/nervousness.

Serious adverse events have been reported during post-approval use of FLOLAN.
These include sepsis, anemia, hypersplenism, thrombocytopenia, pancytopenia, splenomegaly, and hyperthyroidism.

Excessive doses of FLOLAN may acutely result in systemic hypotension, tachycardia, headache, flushing, nausea and vomiting, diarrhea; excessive doses administered chronically can lead to the development of a hyperdynamic state and high-output cardiac failure.*

*Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126(1, suppl):35S-62S.

Please click here for full prescribing information